We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Viral Load Tests Can Help Predict Mpox Severity

By LabMedica International staff writers
Posted on 03 Jul 2025

Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. More...

The disease spreads mainly through direct contact with skin lesions, and patients remain contagious until the lesions fully heal. However, predicting how severe a case will be—or how long a patient may remain infectious—has been a major challenge. Two distinct variants of the virus exist: clade I, which has a higher mortality rate of up to 10%, and clade II, associated with lower mortality. A new study has identified that measuring the level of virus in the blood at the time skin lesions first appear could help predict whether a patient will experience a mild or severe case, offering an important clinical tool for early intervention.

This study was led by researchers at Nagoya University (Nagoya, Japan), in collaboration with other institutions, and focused on developing a predictive model for disease severity based on early viral loads. The research team analyzed medical records from 2007 to 2011 of patients infected with clade Ia mpox in the Democratic Republic of the Congo, the country most affected by the disease. They measured viral load in blood samples taken at the onset of visible skin lesions and used mathematical modelling and machine learning to interpret the data. Patterns in lesion development and symptom severity were used to determine how long patients took to recover and how sick they became. The model identified a viral load threshold of approximately 40,000 copies/mL—above which patients were significantly more likely to suffer severe, long-lasting symptoms and potentially remain contagious for longer.

The study, published in Science Translational Medicine, demonstrated that patients naturally fall into two groups—those with mild symptoms and quick recovery, and those with more severe, prolonged illness. These findings are especially timely as clade I mpox spreads across Africa, prompting renewed global health concern. By enabling early prediction of disease severity, this method could help doctors allocate resources more efficiently, identify high-risk cases faster, and provide more intensive treatment where needed. The team now plans to test the model on the clade Ib variant, which is part of the ongoing outbreak, and explore the use of this tool in guiding real-time clinical decisions in affected regions.

“If this method can be applied to current circulating mpox strains, we can move toward more personalized, data-driven medicine,” said co-lead author Shingo Iwami, professor at the Nagoya University Graduate School of Science. “For patients and their families, this could provide clearer expectations about recovery timelines and reassurance through more precise medical predictions after a frightening diagnosis.”

Related Links:
Nagoya University


New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.